(Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ('Bionor' or the 'Company', ticker 'BIONOR') regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
Primary insider notification - Maja A. Sommerfelt
Maja A. Sommerfelt, a primary insider of the Company, has today exercised 499,377 Subscription Rights and following such transaction holds the following interests in the Company:
Name | Position | Shares |
Subscription Rights in the Rights Issue |
Maja A. Sommerfelt |
VP, Director Research & External Innovation | 818,664 | 0 |
The subscription price for the shares is NOK 0.10 per share.
Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jens Krøis, CFO, +45 208 01 668, jk@bionorpharma.com
Link to announcement in pdf
Bionor Pharma ASA published this content on 26 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 September 2016 08:20:02 UTC.
Original documenthttp://www.bionorpharma.com/en/Media/News/2016/Financial/Mandatory+Notification+of+Trade+-+Sommerfelt.b7C_wlDS3E.ips
Public permalinkhttp://www.publicnow.com/view/D9DB1A38B3DBA346020CC42B6B37E1DEA255E308